HIV prevention drug could reduce cases globally but USAID cuts prevent access, say experts

Injectable PrEP drug, lenacapavir, holds promise for reducing global HIV cases, but US foreign aid cuts limit access for those most in need, warn experts at the Aids 2026 Conference in Brazil.

One year after the World Health Organization's recommendation for expanded access to lenacapavir, a major innovation in HIV prevention, investment in HIV prevention has plummeted worldwide, according to experts. This decline in funding creates a significant barrier to access for individuals who require this life-saving medication, particularly in low-resource settings.

Lenacapavir, administered via annual injections, boasts a 99% efficacy rate in preventing sexually transmitted HIV when used consistently. It joins other PrEP formulations, such as daily oral medications and bimonthly injections, in offering highly effective protection against HIV transmission.

However, without sustained investment from US foreign aid, which was once a crucial supporter of global HIV prevention efforts, those in need may be left without access to this groundbreaking medication. This disparity highlights the urgent need for increased funding and support for HIV prevention initiatives worldwide.